Genetic variation of human UDP-glucuronosyltransferase: Implications in disease and drug glucuronidation

American Journal of PharmacoGenomics

Volumn 3, Issue 1, 2003, Pages 37-52

  Burchell, Brian ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; BILE ACID; BILIRUBIN; CARCINOGEN; CLOFIBRATE; CLOMIPRAMINE; CYTARABINE; DEXTRORPHAN; DIPHENHYDRAMINE; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; FENOFIBRATE; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; IRINOTECAN; LORAZEPAM; MERCAPTOPURINE; PARACETAMOL; PESTICIDE; PIRARUBICIN; PREDNISOLONE; RIFAMPICIN; SAQUINAVIR; STEROID; TOLBUTAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; XENOBIOTIC AGENT; ZIDOVUDINE;

CANCER; CHOLESTASIS; DETOXIFICATION; DIARRHEA; DRUG GLUCURONIDATION; ENZYME MECHANISM; ENZYME SPECIFICITY; GENE ACTIVITY; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HYPERBILIRUBINEMIA; JAUNDICE; MULTIGENE FAMILY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; GENE FREQUENCY; GENETIC DISEASES, INBORN; GLUCURONOSYLTRANSFERASE; HUMANS; MUTATION; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, GENETIC; VARIATION (GENETICS);

EID: 0037223551     PISSN: 11752203     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129785-200303010-00006     Document Type: Review

References (144)

1. Dutton GJ, editor. Glucuronidation of drugs and other compounds. Boca Raton (FL): CRC Press, 1980
2. Clarke DJ, Burchell B. The uridine diphosphate glucuronosyltransferase multigene family: function and regulation. Handb Exper Pharmcol 1994; 112: 3-43
3. Burchell B, McGurk K, Brierley CH, et al. UDP-glucuronosyltransferases. In: Sipes IG, Gandolfi AJ, Mcqueen CA, editors. Comprehensive toxicology. Vol. 3. Amsterdam: Pergamon Elsevier Science, 1997: 401-35
4. Brierley CH, Burchell B. Human UDP-glucuronosyltransferases: chemical defence, jaundice and gene therapy. Bioessays 1993; 15: 749-54
5. Spahn-Langguth H, Benet LZ. Acyl glucuronides revisited: is the glucuronidation process a toxification as well as detoxification mechanism? Drug Metab Rev 1992; 24: 5-48
6. Burchell B, Brierley CH, Rance D. Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation. Life Sci 1995; 57: 1819-31
7. Remmel RP, Burchell B. Validation and use of cloned, expressed human drug metabolising enzymes in heterologous cells for analysis of drug metabolism and drug-drug interactions. Biochem Pharmacol 1993; 46: 559-66
8. Tukey RH, Strassburg CP. Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract. Mol Pharmacol 2001; 59: 405-14
9. Radominska-Pandya A, Czernik PJ, Little JM, et al. Structural and functional studies of UDP-Glucuronosyltransferases. Drug Metab Rev 1999; 31: 817-99
10. Burchell B, Nebert DW, Nelson DR, et al. The UDP glucuronosyltransferase gene superfamily: suggested nomenclature based on evolutionary divergence. DNA Cell Biol 1991; 10: 487-94
11. Mackenzie P, Owens IS, Burchell B, et al. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 1997; 7: 255-69
12. Moghrabi N, Sutherland L, Wooster R, et al. Chromosomal assignment of human phenol and bilirubin UDP-glucuronosyltransferase genes (UGT1A Subfamily). Ann Hum Genet 1992; 56: 83-93
13. Owens IS, Ritter JK. The novel bilirubin/phenol UDP-glucuronosyltransferase UGT 1 gene locus: implications for multiple nonhemolytic familial hyperbilirubinaemia phenotypes. Pharmacogenetics 1992; 2: 93-108
14. Wooster R, Sutherland L, Ebner T, et al. Cloning and stable expression of a new member of the human liver phenol/bilirubin UDP-glucuronosyltransferase cDNA family. Biochem J 1991; 278: 465-9
15. Gong Q-H, Cho JW, Huang T, et al. Thirteen UDP-glucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics 2001; 11: 357-68
16. Pacifici GM, Pelkonen O, editors. Interindividual variability in human drug metabolism. London: Taylor & Francis, 2001
17. Monaghan G, Povey S, Burchell B, et al. Localization of a bile acid UDP-glucuronosyltransferase gene UGT2B to chromosome 4 using the polymerase chain reaction. Genomics 1992; 13: 908-9
18. Monaghan G, Clarke DJ, Povey S, et al. Isolation of a human YAC contig encompassing a cluster of UGT2 genes and its regional localization to chromosome 4q13. Genomics 1994; 23: 496-9
19. Reidy M, Wang J-Y, Miller AP, et al. Genomic organisation of the UGT2B gene cluster on human chromosome 4q13. Pharmacogenetics 2000; 10: 251-60
20. Turgeon D, Carrier J-S, Levesque E, et al. Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 2001; 142: 778-87
21. Jedlitschky G, Cassidy AJ, Sales M, et al. Cloning and characterization of a novel human olfactory UGT. Biochem J 1999; 340: 837-43
22. Tephly TR, Burchell B. The UDP-glucuronosyltransferases: a family of detoxifying enzymes. Trends Pharmacol Sci 1990; 11: 276-9
23. Senafi SB, Clarke DJ, Burchell B. Investigation of the substrate-specificity of a cloned expressed human bilirubin UDP-glucuronosyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation. Biochem J 1994; 303: 233-40
24. Temellini A, Giuliani L, Pacifici GM. Interindividual variability in the glucuronidation and sulphation of ethinyloestradiol in human liver. Br J Clin Pharmacol 1991; 31: 661-4
25. Soars MG, Riley RJ, Findlay KAB, et al. Evidence for significant differences in microsomal drug glucuronidation by canine and human liver and kidney. Drug Metab Dispos 2001; 29: 121-6
26. Burchell B, Coughtrie MWH. UDP-glucuronyltransferases in "genetic factors influencing the metabolism of foreign compounds". Pharmacol Ther 1989; 43: 261-89
27. Vainio H, Elovaara E, Luukkanen L, et al. Expression and co-induction of CYP1A1 and UGT1*6 in human lungs. Eur J Drug Metab Pharmacokinet 1995; Special Issue: 47-8
28. Benowitz NL, Perez-Stable E, Fong I, et al. Ethnic differences in N-glucuronidation of nicotine and cotinine. J Pharmacol Exp Ther 1999; 291: 1196-203
29. Shimoda K, Noguchi T, Ozeki Y, et al. Metabolism of clomipramine in a Japanese psychiatric population: hydroxylation, desmethylation, and glucuronidation. Neuropsychopharmacology 1995; 12: 323-33
30. Bock KW, Schrenk D, Forster A, et al. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 1994; 4: 209-18
31. Liu HF, Vincentviry M, Galteau MM, et al. Urinary glucuronide excretion of fenofibric and clofibric acid glucuronides in man: is it polymorphic. Eur J Clin Pharmacol 1991; 41: 153-9
32. Vincent-Viry M, Cossy C, Galteau MM, et al. Lack of a genetic polymorphism in the glucuronidation of fenofibric acid. Pharmacogenetics 1995; 5: 50-2
33. Duche JC, Querol-Ferrer V, Barre J, et al. Dextromethorphan O-demethylation and dextrorphan glucuronidation in a French population. Int J Clin Pharmacol Ther Toxicol 1993; 31: 392-8
34. Fischer D, Breyer-Pfaff U. Variability of diphenhydramine N-glucuronidation in healthy subjects. Eur J Drug Metab Pharmacokinet 1997; 22: 151-4
35. Sherwood RA, Marsden JT, Stein CA, et al. Intra-individual variation in serum AZT is not related to intestinal absorption or small intestinal inflammatory changes in human HIV-infected subjects. Antivir Chem Chemother 1997; 8: 327-32
36. Bowman ED, Rothman N, Hackl C, et al. Interindividual variation in the levels of certain urinary polycyclic aromatic hydrocarbon metabolites following medicinal exposure to coal tar ointment. Biomarkers 1997; 2: 321-7
37. Court MH, Duan SX, Van Moltke LL, et al. Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther 2001; 299: 988-1006
38. Toide K, Takahashi Y, Yamazaki H, et al. Hepatocyte nuclear factor-1α is a causal factor responsible for interindividual differences in the expression of UDP-Glucuronosyltransferase 2B7 mRNA in human livers. Drug Metab Dispos 2002; 30: 613-5
39. Brierley CH, Senafi SB, Clarke D, et al. Regulation of the human bilirubin UDP-Glucuronosyltransferase gene. Adv Enzyme Regul 1996; 36: 85-97
40. Lee Y-H, Sauer B, Johnson PF, et al. Disruption of the c/ebpα gene in adult mouse liver. Mol Cell Biol 1997; 17: 6014-22
41. Bosma PJ, Roy Chowdhury J, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995; 333: 1171-218
42. Monaghan G, Ryan MF, et al. Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 1996; 347: 578-81
43. Sugatani J, Yamakawa K, Yoshinari K, et al. Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinaemia, Biochem Biophys Res Commun 2002; 292: 492-7
44. Innocenti F, Grimsley C, Das S, et al. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 2002; 12: 725-33
45. Patel M, Tang BK, Grant DM, et al. Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam. Pharmacogenetics 1995; 5: 287-97
46. Bhasker CR, McKinnon W, Stone A, et al. Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 2000; 10: 679-85
47. Koiwai O, Nishizawa M, Hasada K, et al. Gilbert's syndrome is caused by heterozygous missense mutation in the gene for bilirubin UDP-glucuronosyltransferase. Hum Mol Genet 1995; 4: 1183-6
48. Ciotti M, Marrone A, Potter C, et al. Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications. Pharmacogenetics 1997; 7: 485-95
49. Guillemette C, Ritter JK, Auyeung DJ, et al. Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene. Pharmacogenetics 2000; 10: 629-44
50. Vogel A, Kneip S, Barut A, et al. Genetic link of hepatocellular carcinoma with polymorphisms of the UDP-glucuronosyltransferase UGT1A7 gene. Gastroenterology 2001; 121: 1136-44
51. Zheng Z, Guillemette C, Park JY, et al. The tobacco carcinogen-detoxifying enzyme UGT1A7 and its association with oralaryngeal cancer risk in Caucasian and African Americans. J Natl Cancer Inst 2001; 29: 1343-8
52. Huang Y-H, Galijatovic A, Nguyen N, et al. Identification and functional characterization of UDP-glucuronosyltransferases UGT1A8*1. UGT1A8*2 and UGT1A8*3. Pharmacogenetics 2002; 12: 287-97
53. Levesque E, Beaulieu M, Hum D, et al. Characterization and substrate specificity of UGT2B4 (E458), a UDP-Glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics 1999; 9: 207-16
54. Court MH, Duan SX, Guillemette C, et al. Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metab Dispos 2002; 30: 1257-65
55. Levesque E, Beaulieu M, Green MD, et al. T1: islation and characterization of UGT2B15(Y-85): A UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics 1997; 7: 317-25
56. Clarke DJ, Moghrabi N, Monaghan G, et al. Genetic defects of the UDP-glucuronosyltransferase-1 (UGT1) gene that cause familial non-haemolytic unconjugated hyperbilirubinaemias. Clin Chim Acta 1997; 266: 63-74
57. Arias IM. Chronic unconjugated hyperbilirubinaemia without overt signs of hemolysis in adolescents and adults. J Clin Invest 1962; 41: 2233-45
58. Szabo L, Ebrey P. Studies on the inheritance of Crigler-Najjar syndrome by the menthol test. Acta Paediatr Scand 1963; 4: 153-8
59. Arias IM, Gartner LM, Cohen M, et al. Chronic nonhemolytic unconjugated hyperbilirubinemia with glucuronyltransferase deficiency: clinical, biochemical, pharmacologic and genetic evidence for heterogeneity. Am J Med 1969; 47: 395-409
60. Bloomer JR, Berk PD, Howe RB, et al. Bilirubin metabolism in congenital nonhemolytic jaundice. Pediatr Res 1971; 5: 256-64
61. Findlay K, Burchell B. Characterization of the UGTs catalysing thyroid hormone glucuronidation in man. J Clin Endocrinol 2000; 85: 2879-83
62. King CD, Green MD, Rios GR, et al. The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1. Arch Biochem Biophys 1996; 332: 92-100
63. Ebner T, Burchell B, Remmel RP. Human bilirubin UDP-glucuronosyltransferase catalyses the glucuronidation of ethinylestradiol. Mol Pharmacol 1993; 43: 649-54
64. Iyer L, King CD, Whitington PF, et al. Genetic predisposition to the metabolism of irinotecan (CPT11). J Clin Invest 1998; 101: 847-54
65. Moghrabi N, Clarke DJ, Burchell B, et al. Cosegration of intragenic markers with a novel mutation that causes Crigler-Najjar Syndrome type 1: implications for carrier detection and prenatal diagnosis. Am J Hum Genet 1993; 53: 722-9
66. Fevery J. Pathogenesis of Gilbert's syndrome. Eur J Clin Invest 1981; 11: 417-8
67. Macklon AF, Savage RL, Rawlins MD. Gilbert's syndrome and drug metabolism. Clin Pharmacokinet 1979; 4: 223-32
68. Ullrich D, Sieg A, Blume R, et al. Normal pathways for glucuronidation, sulphation and oxidation of paracetamol in Gilbert's syndrome. Eur J Clin Invest 1987; 17: 237-40
69. De Morais SMF, Uetrecht JP, Wells PG. Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert's syndrome. Gastroenterology 1992; 102: 577-86
70. Raijmakers MT, Jansen PL, Steegers EA, et al. Association of human liver bilirubin UDP-glucuronosyltransferase activity with a polymorphism in the promoter region of the UGT1A1 gene. J Hepatol 2000; 33: 348-51
71. Monaghan G, Foster B, Jurima-Romet M, et al. UGT1*1 genotyping in a Canadian inuit population. Pharmacogenetics 1997; 7: 153-6
72. Balram C, Sabapathy K, Fei G, et al. Genetic polymorphisms of UDP-glucuronosyltransferase in Asians: UGT1A1*28 is a common allele in Indians. Pharmacogenetics 2002; 12: 81-3
73. Sampietro M, Lupica L, Perrero L, et al. TATA-box promoter mutant in the promoter of UDP-glucuronosyltransferase gene in Italian patients with Gilbert's syndrome. Ital J Gastroenterol Hepatol 1998; 30: 194-8
74. Biondi ML, Turri O, Dilillo E, et al. Contribution of the TATA-Box genotype (Gilbert's syndrome) to serum bilirubin concentrations in the Italian population. Clin Chem 1999; 45: 897-8
75. Beutler E, Gelbert T, Demina A, et al. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism. Proc Natl Acad Sci U S A 1998; 95: 8170-4
76. te Morsche RHM, Zusterzeel PLM, Raijmakers MTM, et al. Polymorphism in the promoter region of the bilirubin UDP-glucuronosyltransferase (Gilbert's syndrome) in healthy Dutch subjects [letter]. Hepatology 2001; 33: 765
77. Borlak J, Thum T, Landt O, et al. Molecular diagnosis of a familial nonhemolytic hyperbilirubinaemia (Gilbert healthy subjects). Hepatology 2000; 32: 792-5
78. Ando Y, Chida M, Nakayama K, et al. The UGT1A1*28 allele is relatively rare in a Japanese population. Pharmacogenet 1998; 8: 357-60
79. Sato H, Adachi Y, Koiwai O. The genetic basis of Gilbert's syndrome. Lancet 1996; 347: 557-8
80. Akaba K, Kimura T, Sasaki A, et al. Neonatal hyperbilirubinaemia and mutation of bilirubin UDP-glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese. Biochem Mol Biol Int 1998; 46: 21-6
81. Yamamoto K, Sato H, Fujiyama Y, et al. Contribution of two missense mutation (G71R and Y486D) of the bilirubin UDP-glucuronosyltransferase (UGT1A1) gene to phenotypes of Gilbert's syndrome and Crigler-Najjar syndrome type II. Biochim Biophys Acta 1998; 1406: 267-73
82. Aono S, Adachi Y, Uyama E, et al. Analysis of genes for bilirubin UDP-glucuronosyltransferase in Gilbert's syndrome. Lancet 1995; 345: 958-9
83. Huang C-S, Luo G-A, Huang M-H, et al. Variations of the bilirubin in uridine-diphosphoglucuronosyltransferase 1A1 gene in healthy Taiwanese. Pharmacogenetics 2000; 10: 539-44
84. Ciotti M, Owens IS. Evidence for overlapping active sites for 17α-Ethinylestradiol and bilirubin in the human major bilirubin UDPglucuronosyltransferase. Biochem 1996; 35: 10119-24
85. Fisher MB, Vanden Branden M, Findlay K, et al. Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank. Pharmacogenetics 2000; 10: 727-39
86. Wasserman E, Myara A, Lokiec F, et al. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol 1997; 810: 1049-51
87. Gupta E, Mick R, Ramirez J, et al. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 1997; 15: 1502-10
88. Saliba F, Higipantelli R, Misset JL, et al. Pathophysiology and therapy of irinotecan-induced onset diarrhoea in patients with advanced colorectal cancer. J Clin Oncol 1998; 16: 2745-51
89. Ando Y, Saka H, Asai G, et al. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann Oncol 1998; 9: 845-7
90. Iyer L, Hall D, Das S, et al. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 1999; 65: 576-82
91. Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2: 43-7
92. Ando Y, Ueoka H, Sugiyama T, et al. Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan. Ther Drug Monit 2002; 24: 111-6
93. Ciotti M, Basu N, Brangi M, et al. Glucuronidation of 7-Ethyl-10-hydroxycamptothecin (SN38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus. Biochem Biophys Res Commun 1999; 260: 199-202
94. Hanioka N, Ozawa S, Jinno H, et al. Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidfation of 7-ethyl-10-hydroxycamptothecin. Xenobiotica 2001; 31: 687-99
95. Takasuna K, Hagiwara T, Hirohashi M, et al. Inhibition of intestinal microflora beta-glucuronidase modifes the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats. Cancer Chemother Pharmacol 1998; 42: 280-6
96. Maruo Y, Sata H, Bamba N, et al. Chemotherapy-induced unconjugated hyperbilirubinaemia caused by a mutation of the bilirubin uridine-5′-diphosphate glucuronosyltransferase gene. J Pediatr Hematol Oncol 2001; 23: 45-7
97. O'Mara EM, Mummanemi V, Burchell B, et al. Relationship between UDP-glucuronosyltransferase 1A1 genotype and total bilirubin elevation in healthy subjects receiving BMS-232632 and saquinavir [abstract]. 40th ICAAC Meeting; 2000 Sep 17-21. Toronto, Canada
98. Zucker SD, Qin X, Rouster SD, et al. Mechanism of indinavir-induced hyperbilirubinaemia. Proc Natl Acad Sci (USA) 2001; 98: 12671-6
99. Herman RJ, Chaudhary A, Szakacs CB. Disposition of Lorazepam in Gilbert's Syndrome: effects of fasting, feeding, and enterohepatic circulation. J Clin Pharmacol 1994; 34: 978-84
100. Chowdhury RJ, Wolkoff A, Chowdhury RN, et al. Hereditary jaundice and disorders of bilirubin metabolism. In: Scriver CR, Beaudet A, Sly W, et al., editors. The metabolic basis of inherited disease. New York: McGraw-Hill, 1995; 2161-208
101. Onishi S, Kawade N, Itoh S, et al. Postnatal development of uridine, diphosphate glucuronosyltransferase activity towads bilirubin and 2-aminophenol in human liver. Biochem J 1979; 184: 705-7
102. Arias IM, Gartner LM, Seifter S, et al. Prolonged neonatal unconjugated hyperbilirubinaemia associated with breast-feeding and a steroid, pregnane-3α,20β-diol in maternal milk that inhibits glucuronide formation in vitro. J Clin Invest 1964; 43: 2037-47
103. Winfield CR, MacFaul R. Clinical study of prolonged jaundice in breast and bottle-fed babies. Arch Dis Child 1978; 54: 506-7
104. Osborn LM, Reiff M, Bolus R. Jaundice in the full-term neonate. Pediatrics 1984; 73: 520-5
105. Maisels MK, Gifford K, Antle CE, et al. Jaundice in the healthy newborn infant: a new approach to an old problem. Pediatrics 1988; 81: 505-11
106. Maisels MJ, Gifford K. Neonatal jaundice in full-term infants: role of breast-feeding and other causes. Am J Dis Child 1983; 137: 561-2
107. Bancroft JD, Kreamer B, Gourley GR. Gilbert's syndrome accelerates development of neonatal jaundice. J Paediatr 1998; 132: 656-60
108. Monaghan G, McLellan A, McGeechan A, et al. Gilbert's syndrome is a contributory factor in very prolonged unconjugated hyperbilirubinaema of the newborn. J Pediatr 1999; 134: 441-6
109. Saland J, McNamara H, Cohen MI. Navajo jaundice: a variant of neonatal hyperbilirubinaemia associated with breast-feeding. J Pediatr 1974; 85: 271-5
110. Fisher Q, Cohen MI, Curda L. Jaundice and breast-feeding among Alaska Eskimo newborns. Am J Dis Child 1978; 132: 859-63
111. Johnson JD. Jaundice in Navajo neonates. Clin Paediatr (Phila) 1992; 12: 716-8
112. Kaplan M, Hammerman C. Severe neonatal hyperbilirubinaemia: a potential complication of glucose-6-phosphate dehydrogenase deficiency. Clin Perinatol 1998; 25: 575-92
113. Kaplan M, Renbaum P, Levy-Lahad E, et al. Gilbert's syndrome and glucose-6-phosphate dehydrogenase deficiency: a dose-dependent genetic interaction crucial to neonatal hyperbilirubinaemia. Proc Natl Acad Sci U S A 1997; 94: 12128-32
114. Sanpietro M, Lupica L, Perrero L, et al. The expression of UDP-glucuronosyltransferase is a major determinant ofbilirubin level in heterozygous β-thalassaemia and in glucose-6-phosphate dehydrogenase deficiency. Br J Haematol 1997; 99: 437-9
115. Gollanello R, Cipollino MD, Carboni G, et al. Hyperbilirubinaemia, glucose-6-phosphate dehydrogenase deficiency and Gilbert's syndrome. Eur J Pediatr 1999; 158: 914-6
116. Kaplan M, Hammerman C, Renbaum P, et al. Gilbert's syndrome and hyperbilirubinaemia in ABO-incompatible neonates. Lancet 2000; 356: 652-3
117. del Guidice EM, Perotta S, Nobili B, et al. Coinheritance of Gilbert's syndrome increases the risk of developing gallstones in patients with hereditary spherocytosis. Blood 1999; 94: 2259-62
118. Perrotta S, del Giudice EM, Carbane R, et al. Gilbert's syndrome accounts for the phenotypic variability of congenital dyserthropoietic anaemia type II. J Pediatr 2000; 136: 556-9
119. Kaplan M, Hammerman C, Rubaltelli FF, et al. Hemolysis and bilirubin conjugation in association with UDP-glucuronosyltransferase 1A1 promoter polymorphism. Hepatology 2002; 35: 905-11
120. Trioche P, Chalas J, Francoual J, et al. Jaundice with hypertrophic pyloric stenosis as an early manifestation of Gilbert's Syndrome. Arch Dis Child 1999; 81: 301-3
121. Galanello R, Cipollina MD, Dessi C, et al. Co-inherited Gilbert's syndrome: a factor determining hyperbilirubinaemia in homozygous beta-thalassemia. Haematologica 1999; 84: 103-5
122. McKie K, Kutlar F, Sromek S, et al. UDP-glucuronosyltransferase (UGT1A1) promoter polymorphism and bilirubin levels in patients with sickle cell disease [abstract 861]. Blood 1999; 94: P197a
123. Passon RG, Howard TA, Zimmerman SA, et al. The effect of UDP-glucuronosyltransferase (UGT1A1) promoter polymorphisms on serum bilirubin levels and cholelthiasis in patients with sickle cell anaemia [abstract 2865]. Blood 1999; 94: P645a
124. Doyama H, Okada T, Kobayashi T, et al. Effect of bilirubin UDP-glucuronosyltransferase 1 gene TATA box genotypes on serum bilirubin concentrations in chronic liver injuries. Hepatology 2000; 32: 563-8
125. Guillemette C, Millikan RC, Newman B, et al. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. Cancer Res 2000; 60: 950-6
126. Bock KW, Forster A, Gschaidmeier H, et al. Paracetamol glucuronidation by recombinant rat and human phenol UDP-glucuronosyltransferase. Biochem Pharmacol 1993; 45: 1809-14
127. Osborne NJ, Tonkin AL, Miners JO. Interethnic differences in drug glucuronidation: a comparison of paracetamol metabolism in Caucasians and Chinese. Br J Clin Pharmacol 1991; 32: 765-7
128. Ebner T, Burchell B. Substrate specificities of two stably expressed human liver UDP-glucuronosyltransferases of the UGT1 gene family. Drug Metab Dispos 1993; 21: 50-5
129. Cheng Z, Radominska-Paydya A, Tephly TR. Cloning and expression of human UDP-glucuronosyltransferase 1A8. Arch Biophys Biochem 1998; 356: 301-5
130. Lautala P, Ethell B, Burchell B, et al. The COMT inhibitors and entacapone and tolcapone are good substrates for UGT1A4 and UGT1A9. Drug Metab Dispos 2000; 28: 1385-9
131. Strassburg CP, Mann MP, Tukey RH. Expression of the UDP-glucuronosyltransferase 1A locus in human colon. J Biol Chem 1998; 273: 8719-26
132. Fournel-Gigleux S, Jackson MR, Wooster R, et al. Expression of a human liver cDNA encoding hydeoxycholic acid UDP-glucuronosyltransferase in cell culture. FEBS Lett 1989; 243: 119-22
133. Pillot T, Ouzzine M, Fournel-Gigleux S, et al. Glucuronidation of hyodeoxycholic acid in human liver: evidence for a selective role of UGT2B4. J Biol Chem 1993; 268: 25636-42
134. Jin CJ, Miners JO, Lillywhite KJ, et al. Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltranferase glucuronidating carboxylic acid-containing drugs. J Pharmacol Exp Ther 1993; 264: 475-9
135. Ritter JK, Chen F, Sheen YY, et al. Two human liver cDNAs encode UDP-glucuronosyltransferase with 2 log differences in activity toward parallel substrates including hyodeoxycholic acid and certain estrogen derivatives. Biochem 1992; 31: 3409-14
136. Jin CJ, Mackenzie PI, Miners JO. The regio- and stereo-selectivity of C19 and C21 hydroxysteroid glucuronidation by UGT2B7 and UGT2B11. Arch Biochem Biophys 1997; 341: 207-11
137. Coffman BL, Rios GR, King CD, et al. Human UGT2B7 catalyses morphine glucuronidation. Drug Metab Dispos 1997; 25: 1-4
138. Patel M, Tang BK, Kalow W, (S) Oxazepam glucuronidation is inhibited by ketoprofen and other substrates of UGT 2B7. Pharmacogentics 1995; 5: 43-29
139. Coffman BL, King CD, Rios GR, et al. The glucuronidation of opioids, other xenobiotics and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos 1998; 26: 73-7
140. Yue QY, Svensson JO, Alm C, et al. Interindividual and interethnic differences in the demethylation and glucuronidation of codeine. Br J Clin Pharmacol 1989; 28: 629-37
141. Yue Q-Y, Svensson J-O, Sawe J, et al. Codeine metabolism in three oriental populations: a pilot study in Chinese. Japanese and Koreans. Pharmacogenetics 1995; 5: 173-7
142. Green MD, Oturu EM, Tephly TR. Stable expression of a human liver UDP-glucuronosyltransferase (UGT2B15) with activity toward steroid and xenobiotic substrates. Drug Metab Dispos 1994; 22: 799-805
143. MacLeod SL, Nowell SA, Lang NP. Determination of genetic polymorphisms in UGT2B15 by allele-specific PCR. Ann Surg Oncol 2000; 7: 777-82
144. Lampe JW, Bigler J, Bush AC, et al. Prevalence of polymorphisms in the human UDP-glucuronosyltransferase 2B family: UGT2B4 ((DE)-E-458), UGT2B7 ((HY)-Y-268), and UGT2B15((DY)-Y-85). Cancer Epidemiol Biomarkers Prev 2000; 9: 329-33